Lyme Disease Vaccine: Vax-Before-Travel – No Vaccine This Year
The Lyme Disease Vaccine: A Complete Guide to VLA15 and the Future of Prevention (August 12, 2025)
Table of Contents
As of August 12, 2025, the prospect of a widely available Lyme disease vaccine is closer than ever before. With the Phase 3 clinical trial of VLA15, developed by Valneva SE and partnered with Pfizer, currently underway, a new era in preventing this debilitating tick-borne illness may be on the horizon. This article provides a comprehensive overview of Lyme disease, the VLA15 vaccine candidate, the current state of its development, and what the future holds for Lyme disease prevention.
Understanding Lyme Disease: Prevalence, Symptoms, and Risks
Lyme disease is the most common vector-borne illness in North America and Europe, posing a significant and growing public health challenge. Transmitted to humans through the bite of infected blacklegged ticks (also known as deer ticks), the disease is caused by the bacterium Borrelia burgdorferi and, less commonly, Borrelia mayonii.
The Expanding Geographic Range and Increasing Incidence
Historically concentrated in the northeastern and mid-Atlantic regions of the United States, Lyme disease is now spreading geographically. The CDC reports over 89,000 cases reported by state health departments in 2023.However, this number is believed to be a significant underestimation. Alternative estimates suggest approximately 476,000 Americans are diagnosed and treated for lyme disease annually. This expansion is linked to factors like climate change, which allows ticks to survive and thrive in previously inhospitable areas, and changes in animal populations.In Europe, the highest incidence rates are found in Scandinavia, the Baltic states, and Central European countries like Austria, the czech republic, Germany, and Slovenia.
Recognizing the Symptoms of Lyme Disease
Early symptoms of Lyme disease, appearing within 3-30 days of a tick bite, ofen include:
Erythema Migrans (EM) Rash: A characteristic “bull’s-eye” rash, though not everyone develops this.
Flu-like Symptoms: Fever, chills, fatigue, headache, and muscle aches.
If left untreated, Lyme disease can progress to more severe complications affecting the joints, heart, and nervous system. These later-stage symptoms can include:
Lyme Arthritis: Severe joint pain and swelling, especially in the knees.
Neurological Problems: Facial palsy (loss of muscle tone on one side of the face), meningitis, and nerve pain.
Cardiac Issues: irregular heartbeat.
Early diagnosis and treatment with antibiotics are crucial to prevent these long-term health problems.
VLA15: A Promising New Lyme Disease Vaccine
VLA15 represents a significant advancement in Lyme disease prevention. Developed by Valneva SE and now co-developed with Pfizer,this vaccine candidate offers a multi-pronged approach to protection.
How VLA15 Works: A Multivalent Recombinant Protein Vaccine
VLA15 is a multivalent recombinant protein vaccine, meaning it utilizes specific proteins from the Borrelia bacteria to stimulate an immune response. Crucially, it targets six of the most prevalent Borrelia serotypes found in both the united States and Europe. This broad-spectrum approach is designed to provide protection against the majority of Lyme disease-causing strains. Unlike some earlier vaccine attempts, VLA15 does not utilize live bacteria, minimizing potential safety concerns. The vaccine works by prompting the body to produce antibodies that recognize and neutralize the Borrelia bacteria, preventing infection upon tick bite.
phase 3 Trial Progress and Expected Timeline
Currently, Pfizer is conducting a randomized, placebo-controlled Phase 3 field efficacy study. Participants are being monitored for Lyme disease cases throughout the 2025 Lyme disease season (until the end of October). Topline data from this trial are anticipated as soon as all confirmed Lyme disease cases are analyzed.
Valneva and pfizer are aiming to submit a Biologics License Submission (BLA) to the U.S.Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in 2026, contingent upon positive Phase 3 trial results.Prosperous submission and approval would pave the way for widespread availability of the vaccine.
Current Prevention Strategies and the Role of a Vaccine
Currently, preventing Lyme disease relies on a combination of personal protective measures and, in some cases, post-exposure prophylaxis.
Existing prevention Methods
**Tick Avoidance